Cargando…

Therapeutic targeting with DABIL‐4 depletes myeloid suppressor cells in 4T1 triple‐negative breast cancer model

In many solid tumors including triple‐negative breast cancer (TNBC), upregulation of the interleukin‐4 receptor (IL‐4R) has been shown to promote cancer cell proliferation, apoptotic resistance, metastatic potential, and a Th2 response in the tumor microenvironment (TME). Since immunosuppressive cel...

Descripción completa

Detalles Bibliográficos
Autores principales: Parveen, Sadiya, Siddharth, Sumit, Cheung, Laurene S., Kumar, Alok, Shen, Jessica, Murphy, John R., Sharma, Dipali, Bishai, William R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8096791/
https://www.ncbi.nlm.nih.gov/pubmed/33682324
http://dx.doi.org/10.1002/1878-0261.12938
_version_ 1783688217350897664
author Parveen, Sadiya
Siddharth, Sumit
Cheung, Laurene S.
Kumar, Alok
Shen, Jessica
Murphy, John R.
Sharma, Dipali
Bishai, William R.
author_facet Parveen, Sadiya
Siddharth, Sumit
Cheung, Laurene S.
Kumar, Alok
Shen, Jessica
Murphy, John R.
Sharma, Dipali
Bishai, William R.
author_sort Parveen, Sadiya
collection PubMed
description In many solid tumors including triple‐negative breast cancer (TNBC), upregulation of the interleukin‐4 receptor (IL‐4R) has been shown to promote cancer cell proliferation, apoptotic resistance, metastatic potential, and a Th2 response in the tumor microenvironment (TME). Since immunosuppressive cells in the TME and spleen including myeloid‐derived suppressor cells (MDSCs) and tumor‐associated macrophages (TAMs) also express the IL‐4R, we hypothesized that selective depletion of IL‐4R‐bearing cells in TNBC would result in the direct killing of tumor cells and the depletion of immunosuppressive cells and lead to an enhanced antitumor response. To selectively target IL‐4R(+) cells, we employed DABIL‐4, a fusion protein toxin consisting of the catalytic and translocation domains of diphtheria toxin fused to murine IL‐4. As anticipated, DABIL‐4 has potent cytotoxic activity against TNBC cells both in vitro and in vivo. We demonstrate in the murine 4T1 TNBC model that DABIL‐4 significantly reduces tumor growth, splenomegaly, and lung metastases. Importantly, we also show that the administration of DABIL‐4 results in the selective depletion of MDSCs, TAMs, and regulatory T cells in treated mice, with a concomitant increase in IFN‐γ(+) CD8 effector T cells in the TME. Since the 4T1 antitumor activity of DABIL‐4 was largely diminished in IL‐4R knockout mice, we postulate that DABIL‐4 functions primarily as an immunotherapeutic by the depletion of MDSCs, TAMs, and regulatory T cells. NanoString analysis of control and treated tumors confirmed and extended these observations by showing a marked decline of mRNA transcripts that are associated with tumorigenesis and metastasis. In conclusion, we demonstrate that DABIL‐4 targeting of both tumor and immunosuppressive host cells likely represents a novel and effective treatment strategy for 4T1 TNBC and warrants further study.
format Online
Article
Text
id pubmed-8096791
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-80967912021-05-10 Therapeutic targeting with DABIL‐4 depletes myeloid suppressor cells in 4T1 triple‐negative breast cancer model Parveen, Sadiya Siddharth, Sumit Cheung, Laurene S. Kumar, Alok Shen, Jessica Murphy, John R. Sharma, Dipali Bishai, William R. Mol Oncol Research Articles In many solid tumors including triple‐negative breast cancer (TNBC), upregulation of the interleukin‐4 receptor (IL‐4R) has been shown to promote cancer cell proliferation, apoptotic resistance, metastatic potential, and a Th2 response in the tumor microenvironment (TME). Since immunosuppressive cells in the TME and spleen including myeloid‐derived suppressor cells (MDSCs) and tumor‐associated macrophages (TAMs) also express the IL‐4R, we hypothesized that selective depletion of IL‐4R‐bearing cells in TNBC would result in the direct killing of tumor cells and the depletion of immunosuppressive cells and lead to an enhanced antitumor response. To selectively target IL‐4R(+) cells, we employed DABIL‐4, a fusion protein toxin consisting of the catalytic and translocation domains of diphtheria toxin fused to murine IL‐4. As anticipated, DABIL‐4 has potent cytotoxic activity against TNBC cells both in vitro and in vivo. We demonstrate in the murine 4T1 TNBC model that DABIL‐4 significantly reduces tumor growth, splenomegaly, and lung metastases. Importantly, we also show that the administration of DABIL‐4 results in the selective depletion of MDSCs, TAMs, and regulatory T cells in treated mice, with a concomitant increase in IFN‐γ(+) CD8 effector T cells in the TME. Since the 4T1 antitumor activity of DABIL‐4 was largely diminished in IL‐4R knockout mice, we postulate that DABIL‐4 functions primarily as an immunotherapeutic by the depletion of MDSCs, TAMs, and regulatory T cells. NanoString analysis of control and treated tumors confirmed and extended these observations by showing a marked decline of mRNA transcripts that are associated with tumorigenesis and metastasis. In conclusion, we demonstrate that DABIL‐4 targeting of both tumor and immunosuppressive host cells likely represents a novel and effective treatment strategy for 4T1 TNBC and warrants further study. John Wiley and Sons Inc. 2021-03-24 2021-05 /pmc/articles/PMC8096791/ /pubmed/33682324 http://dx.doi.org/10.1002/1878-0261.12938 Text en © 2021 The Authors. Molecular Oncology published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Articles
Parveen, Sadiya
Siddharth, Sumit
Cheung, Laurene S.
Kumar, Alok
Shen, Jessica
Murphy, John R.
Sharma, Dipali
Bishai, William R.
Therapeutic targeting with DABIL‐4 depletes myeloid suppressor cells in 4T1 triple‐negative breast cancer model
title Therapeutic targeting with DABIL‐4 depletes myeloid suppressor cells in 4T1 triple‐negative breast cancer model
title_full Therapeutic targeting with DABIL‐4 depletes myeloid suppressor cells in 4T1 triple‐negative breast cancer model
title_fullStr Therapeutic targeting with DABIL‐4 depletes myeloid suppressor cells in 4T1 triple‐negative breast cancer model
title_full_unstemmed Therapeutic targeting with DABIL‐4 depletes myeloid suppressor cells in 4T1 triple‐negative breast cancer model
title_short Therapeutic targeting with DABIL‐4 depletes myeloid suppressor cells in 4T1 triple‐negative breast cancer model
title_sort therapeutic targeting with dabil‐4 depletes myeloid suppressor cells in 4t1 triple‐negative breast cancer model
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8096791/
https://www.ncbi.nlm.nih.gov/pubmed/33682324
http://dx.doi.org/10.1002/1878-0261.12938
work_keys_str_mv AT parveensadiya therapeutictargetingwithdabil4depletesmyeloidsuppressorcellsin4t1triplenegativebreastcancermodel
AT siddharthsumit therapeutictargetingwithdabil4depletesmyeloidsuppressorcellsin4t1triplenegativebreastcancermodel
AT cheunglaurenes therapeutictargetingwithdabil4depletesmyeloidsuppressorcellsin4t1triplenegativebreastcancermodel
AT kumaralok therapeutictargetingwithdabil4depletesmyeloidsuppressorcellsin4t1triplenegativebreastcancermodel
AT shenjessica therapeutictargetingwithdabil4depletesmyeloidsuppressorcellsin4t1triplenegativebreastcancermodel
AT murphyjohnr therapeutictargetingwithdabil4depletesmyeloidsuppressorcellsin4t1triplenegativebreastcancermodel
AT sharmadipali therapeutictargetingwithdabil4depletesmyeloidsuppressorcellsin4t1triplenegativebreastcancermodel
AT bishaiwilliamr therapeutictargetingwithdabil4depletesmyeloidsuppressorcellsin4t1triplenegativebreastcancermodel